AGMB-129

Circulating DNA/RNA Market Set to Triple to $16.4 Billion by 2032, Driven by Patent Innovations

2 months ago

• The global circulating DNA/RNA market is projected to grow from $5.32 billion in 2023 to $16.4 billion by 2032, advancing at a CAGR of 13.29% according to a new patent landscape report. • Key industry players Nantomics, Genentech, and Novartis are leading innovation in the sector, with the United States dominating patent activity with over 600 patents, followed by Europe and Asia. • The oncology segment leads patent filings, with technological advancements in non-invasive diagnostics and personalized medicine driving market expansion and creating new opportunities in genomic medicine.

Agomab's AGMB-129 Shows Promising Results in Phase 2a Trial for Fibrostenosing Crohn's Disease

2 months ago

• Agomab Therapeutics announced positive interim results from the STENOVA Phase 2a trial, with AGMB-129 meeting all primary and secondary endpoints in fibrostenosing Crohn's disease patients after 12 weeks of treatment. • AGMB-129, an oral GI-restricted ALK5 inhibitor targeting the TGF-β pathway, demonstrated favorable safety and tolerability with high local exposure in the ileum but minimal systemic exposure. • The company has initiated an open-label extension study allowing participants to receive treatment for up to 48 additional weeks, addressing a significant unmet need in a condition affecting nearly 50% of Crohn's disease patients.

Circulating DNA/RNA Market Set to Triple to $16.4 Billion by 2032, Driven by Patent Innovations

Agomab's AGMB-129 Shows Promising Results in Phase 2a Trial for Fibrostenosing Crohn's Disease

Drug Development Updates